Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1985 1
1986 6
1987 29
1988 57
1989 104
1990 117
1991 164
1992 191
1993 251
1994 240
1995 266
1996 271
1997 287
1998 293
1999 276
2000 313
2001 300
2002 324
2003 336
2004 330
2005 378
2006 360
2007 336
2008 376
2009 445
2010 454
2011 465
2012 473
2013 526
2014 583
2015 652
2016 747
2017 756
2018 823
2019 894
2020 1128
2021 1310
2022 1371
2023 1303
2024 471

Text availability

Article attribute

Article type

Publication date

Search Results

16,369 results

Results by year

Filters applied: . Clear all
Page 1
A safe and potent anti-CD19 CAR T cell therapy.
Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, Duan P, Lin Y, Zheng W, Wang X, Lin N, Tu M, Xie Y, Zhang C, Liu W, Deng L, Gao S, Ping L, Wang X, Zhou N, Zhang J, Wang Y, Lin S, Mamuti M, Yu X, Fang L, Wang S, Song H, Wang G, Jones L, Zhu J, Chen SY. Ying Z, et al. Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011207 Free PMC article. Clinical Trial.
Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3zeta domains. ...Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma respon …
Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulator …
Treatment of SLE with anti-CD19 CAR-T cells.
Carney EF. Carney EF. Nat Rev Nephrol. 2022 Dec;18(12):743. doi: 10.1038/s41581-022-00651-3. Nat Rev Nephrol. 2022. PMID: 36323874 No abstract available.
CD19-CAR trials.
Ramos CA, Savoldo B, Dotti G. Ramos CA, et al. Cancer J. 2014 Mar-Apr;20(2):112-8. doi: 10.1097/PPO.0000000000000031. Cancer J. 2014. PMID: 24667955 Free PMC article. Review.
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). ...
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. …
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Kochenderfer JN, et al. Blood. 2010 Nov 11;116(19):3875-86. doi: 10.1182/blood-2010-01-265041. Epub 2010 Jul 14. Blood. 2010. PMID: 20631379 Free PMC article.
To evaluate anti-CD19-CAR-transduced T cells in a murine model of adoptive T-cell therapy, we developed a CAR that specifically recognized murine CD19. ...Anti-CD19-CAR-transduced T cells had superior antilymphoma efficacy compared with the anti-CD19 m …
To evaluate anti-CD19-CAR-transduced T cells in a murine model of adoptive T-cell therapy, we developed a CAR that specifically recog …
CD19, from bench to bedside.
Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S, Xu Y. Li X, et al. Immunol Lett. 2017 Mar;183:86-95. doi: 10.1016/j.imlet.2017.01.010. Epub 2017 Jan 30. Immunol Lett. 2017. PMID: 28153605 Review.
Co-ligation of CD19 with the BCR synergistically enhances calcium release, mitogen-activated protein kinase activity and cell proliferation. ...Here in this review, we summarize the latest development on the major functions of CD19 as both positive and negative regu …
Co-ligation of CD19 with the BCR synergistically enhances calcium release, mitogen-activated protein kinase activity and cell prolife …
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH, Kim Y, Lee HK, Lee SM, Jeong HG, Choi SU, Park CH. Kang CH, et al. Int J Mol Sci. 2020 Dec 1;21(23):9163. doi: 10.3390/ijms21239163. Int J Mol Sci. 2020. PMID: 33271901 Free PMC article.
In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line for screening of CD19 scFvs because it has advantages in terms of cell culture and gene transduction compared to primary T cells. Using …
In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line fo …
Deficiencies in the CD19 complex.
Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Wentink MWJ, et al. Clin Immunol. 2018 Oct;195:82-87. doi: 10.1016/j.clim.2018.07.017. Epub 2018 Jul 31. Clin Immunol. 2018. PMID: 30075290 Review.
Signaling via the CD19-complex, consisting of CD19, CD81, CD21 and CD225, is critically important for B-cell development, differentiation and maturation. ...Over the past decade, 15 patients with antibody deficiency due to deficiencies in the CD19-complex hav …
Signaling via the CD19-complex, consisting of CD19, CD81, CD21 and CD225, is critically important for B-cell development, diff …
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
Viardot A, Sala E. Viardot A, et al. Expert Opin Investig Drugs. 2021 Jul;30(7):773-784. doi: 10.1080/13543784.2021.1928074. Epub 2021 Jul 13. Expert Opin Investig Drugs. 2021. PMID: 33998346 Review.
CD19 is widely expressed on B-ALL and nearly ideal for immunotherapy because of strong 'on target' but manageable 'off target' effects. ...We discuss novel strategies on approved anti-CD19 immunotherapies. The focus is on experimental anti-CD19 antibodies or …
CD19 is widely expressed on B-ALL and nearly ideal for immunotherapy because of strong 'on target' but manageable 'off target' effect …
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, Costu E, Taylor J, Bulek A, Srivastava S, Gannon I, Jha R, Gealy R, Stanczuk L, Rizou T, Robson M, El-Kholy M, Baldan V, Righi M, Sillibourne J, Thomas S, Onuoha S, Cordoba S, Pule M. Kokalaki E, et al. Mol Ther. 2023 Jul 5;31(7):2089-2104. doi: 10.1016/j.ymthe.2023.03.020. Epub 2023 Mar 21. Mol Ther. 2023. PMID: 36945773 Free article.
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause of relapse. ...We found no correlation between affinity or membrane proximity of recognition epitope within Ig domains 3-6 of CD22 with CAR …
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause …
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy.
Naddafi F, Davami F. Naddafi F, et al. Int J Mol Cell Med. 2015 Summer;4(3):143-51. Int J Mol Cell Med. 2015. PMID: 26629482 Free PMC article. Review.
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. ...For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, an …
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune disea …
16,369 results
You have reached the last available page of results. Please see the User Guide for more information.